• Publications
  • Influence
A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain
ABSTRACT Objective: To evaluate the relative efficacy and tolerability of tapentadol immediate release (IR) and oxycodone IR for management of moderate to severe pain following orthopedic surgeryExpand
  • 109
  • 5
  • Open Access
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III,
OBJECTIVES The primary objective of this study was to assess the efficacy and tolerability of tapentadol immediate release (IR) in patients who were candidates for joint replacement surgery due toExpand
  • 149
  • 3
Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
Abstract We treated a 57-year-old woman for refractory inflammatory bowel disease with a humanized anti–tumor necrosis factor α monoclonal antibody (Infliximab). The patient also had a 15-yearExpand
  • 200
  • 2
Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open‐Label, Crossover, Drug‐Drug Interaction Studies
Study Objective. To evaluate the effects of acetaminophen, naproxen, and acetylsalicylic acid on the pharmacokinetics of the centrally acting analgesic tapentadol in healthy subjects.
  • 36
  • 1
Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.
INTRODUCTION CVT-301 is an orally inhaled levodopa therapy approved for the intermittent treatment of OFF episodes in Parkinson's disease patients who are taking a standard oral levodopa regimen.Expand
  • 3
  • 1
Efficacy results of a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson’s disease (P2.8-048)
Objective: To present the efficacy results from a 12-month safety and efficacy extension of a phase 3 study of CVT-301, a levodopa inhalation powder in development for the treatment of OFF symptoms.Expand
  • 1
  • 1
Bacteriology in Patients with Chronic Sinusitis who have been Medically and Surgically Treated
Chronic sinusitis is a disease that afflicts a significant percentage of the population and causes considerable long-term morbidity. The common use of multiple broad-spectrum oral antibiotics andExpand
  • 28
  • Open Access
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
BACKGROUND CVT-301 (Inbrija) is a self-administered orally inhaled levodopa approved for the intermittent treatment of OFF episodes in patients with Parkinson's disease (PD) treated withExpand
  • 8
Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
Objective: To characterize the pulmonary safety of CVT-301 84 mg vs standard-of-care over 12 months. Background: CVT-301 is an investigational therapy that delivers levodopa to the lungs. It isExpand
  • 3
Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
Objective: To characterize open-label efficacy of CVT-301 84 mg over 12 months. Background: CVT-301 is an investigational therapy that delivers levodopa to the lungs. It is intended to treat OFFExpand
  • 3